US Food and Drug Administration. Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics. http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM277916.pdf. Accessed December 30, 2014.
US Food and Drug Administration. Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics. Modified 12/2014. www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM311290.pdf. Accessed February 22, 2015.
US Food and Drug Administration. Questions and Answers: FDA Approves a Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting (ER/LA) Opioid Analgesics. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm309742.htm. Accessed December 30, 2014.
Substance Abuse and Mental Health Services Administration. 2011. Results from the 2010 National Survey on Drug Use and Health: Detailed Table, Table 7.1.a. Rockville, MD. http://www.samhsa.gov/data/NSDUH/2k10NSDUH/tabs/Sect7peTabs1to45.htm#Tab7.1A. Accessed May 24, 2014.
Substance Abuse and Mental Health Services Administration. 2011. Drug Abuse Warning Network, 2009: National Estimates of Drug-Related Emergency Department Visits, Table 19. Rockville, MD. http://www.samhsa.gov/data/2k11/DAWN/2k9DAWNED/HTML/DAWN2k9ED.htm#Tab19. Accessed on May 24, 2014.
Warner M, Chen LH, Makuc DM, Anderson RN, Miniño AM. 2011. Drug Poisoning Deaths in the United States, 1980–2008, in Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, NCHS Data Brief, No 81. December 2011. Hyattsville, MD. http://www.cdc.gov/nchs/data/databriefs/db81.pdf. Accessed May 24, 2014.
Collaborative for REMS Education. ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care. October 14, 2014. www.core-rems.org/tools/updates. Accessed December 30, 2014.
Collaborative for REMS Education. Tools and Resources. www.core-rems.org/tools/updates. Accessed December 30, 2014.
Brennan MJ. Update on prescription extended-release opioids and appropriate patient selection. J Multidiscip Health. 2013;6:265-280.
National Institute on Drug Abuse. Glossary. Commonly Used Terms In Addiction Science. http://www.drugabuse.gov/publications/media-guide/glossary. Accessed December 23, 2014.
Smith SM, Dart RC, Katz NP, et al., Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain. 2013;154(11):2287-2296.
Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain. Prepared by the Management of Opioid Therapy for Pain Working Group. 2010. http://www.healthquality.va.gov/cot/cot_310_sum.pdf. Accessed April 18, 2013.
Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113-130. Abstract
Zacharoff KL, McCarberg BH, Reisner L, Venuti SW. Managing Chronic Pain with Opioids in Primary Care. 2nd ed. Newton, MA: Inflexion, Inc.; 2010.
Heapy A, Kerns RD. Psychological and behavioral assessment. In: Benzon HT, Rathmell JP, Wu CL, Turk DC, Argoff CE, eds. Raj's Practical Management of Pain. 4th ed. Philadelphia, PA: Mosby-Elsevier; 2008:279-295.
Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med. 2005;6:432-442. Abstract
Passik SD, Kirsh KL, Casper D. Addiction-related assessment tools and pain management. Pain Med. 2008;(Suppl 9):S145-S166.
Substance Abuse and Mental Health Services Administration. Screening, Brief Intervention and Referral to Treatment (SBIRT) in Behavioral Healthcare. http://www.samhsa.gov/prevention/SBIRT/SBIRTwhitepaper.pdf. Accessed April 18, 2013.
Lalani I, Argoff CE. History and physical examination of the pain patient. In: Benzon HT, Rathmell JP, Wu CL, Turk DC, Argoff CE, eds. Raj's Practical Management of Pain. 4th ed. Philadelphia, PA: Mosby-Elsevier; 2008:177-188.
Substance Abuse and Mental Health Services Administration. Managing Chronic Pain in Adults With or in Recovery From Substance Use Disorders. Treatment Improvement Protocol (TIP) Series 54. HHS Publication No. (SMA) 12-4671. 2011. Rockville, MD.
Ferrell B, Argoff CE, Epplin J, et al. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57:1331-1346. Abstract
Berde CB, Walco GA, Krane EJ, et al. Pediatric analgesic clinical trial designs, measures, and extrapolation: report of an FDA scientific workshop. Pediatrics. 2012;129:354-364. Abstract
Fine PG, Portenoy RK. Establishing "best practices" for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage. 2009;38:418-425. Abstract
Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage. 2009;38:426-439. Abstract
Pasternak GW. Multiple opiate receptors: deja vu all over again. Neuropharmacology. 2004;47(Suppl 1):312-323. Abstract
Periyakoil V. End of Life Online Curriculum. Pain Control: Opioid Conversion Module. http://endoflife.stanford.edu/M11_pain_control/intro_m01.html. Accessed February 22, 2015.27.
Shaheen PE, Walsh D, Lasheen W, Davis MP, Lagman RL. Opioid equianalgesic tables: are they all equally dangerous? J Pain Symptom Manage. 2009;38:409-417.
Webster LR, Fine PG. Review and critique of opioid rotation practices and associated risks of toxicity. Pain Med. 2012;13:562-570. Abstract
Haffey F, Brady RR, Maxwell S. A comparison of the reliability of smartphone apps for opioid conversion. Drug Saf. 2013;36:111-117. Abstract
Chou R, Fanciullo GJ, Fine PG, et al. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10:131-146. Abstract
Current Opioid Misuse Measure (COMM)™. PainEDU website. https://www.painedu.org. Accessed June 23, 2013.
Butler SF, Budman SH, Fanciullo GJ, Jamison RN. Cross validation of the current opioid misuse measure to monitor chronic pain patients on opioid therapy. Clin J Pain. 2010;26:770-776. Abstract
Meltzer EC, Rybin D, Saitz R, et al. Identifying prescription opioid use disorder in primary care: diagnostic characteristics of the Current Opioid Misuse Measure (COMM). Pain. 2011;152:397-402. Abstract
Fleming MF, Davis J, Passik SD. Reported lifetime aberrant drug-taking behaviors are predictive of current substance use and mental health problems in primary care patients. Pain Med. 2008;9:1098-1106. Abstract
Passik SD, Messina J, Golsorkhi A, Xie F. Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain. J Pain Symptom Manage. 2011;41:116-125. Abstract
Portenoy RK. Opioid therapy for chronic nonmalignant pain: clinician's perspective. J Law Med Ethics. 1996;24:296-309. Abstract
Passik SD, Kirsh KL, Donaghy KB, Portenoy RK. Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse. Clin J Pain. 2006;22:173-181. Abstract
Compton P. Should opioid abusers be discharged from opioid-analgesic therapy? Pain Med. 2008;9:383-390.
Gourlay DL, Heit HA. Compliance monitoring in chronic pain management. In: Fishman SM, Ballantyne JC, Rathmell JP, eds. Bonica's Management of Pain. 4th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2010:854-859.
Perrone J, Nelson LS. Medication reconciliation for controlled substances--an "ideal" prescription-drug monitoring program. N Engl J Med. 2012;366:2341-2343. Abstract
Clark T, Eadie J, Kreiner P, Strick G. Prescription Drug Monitoring Programs: An Assessment of the Evidence for Best Practices. http://www.pdmpexcellence.org/sites/all/pdfs/Brandeis_PDMP_Report_final.pdf. Accessed February 22, 2015.
Gugelmann HM, Perrone J. Can prescription drug monitoring programs help limit opioid abuse? JAMA. 2011;306:2258-2259.
Substance Abuse and Mental Health Services Administration. Clinical Drug Testing in Primary Care. Technical Assistance Publication (TAP) 32. HHS Publication No.(SMA) 12-4668. Rockville, MD: US Department of Health and Human Services; 2012.
Gourlay DL, Heit HA, Caplan YH. Urine Drug Testing in Clinical Practice. The Art and Science of Patient Care. 4th ed. San Francisco, CA: California Academy of Family Providers; 2010.
Christo PJ, Manchikanti L, Ruan X, et al. Urine drug testing in chronic pain. Pain Physician. 2011;14:123-143. Abstract
Gourlay DL, Heit HA. Universal precautions revisited: managing the inherited pain patient. Pain Med. 2009;10(Suppl 2):S115-S123. Abstract
Von Seggern RL, Fitzgerald CP, Adelman LC, Adelman JU. Laboratory monitoring of OxyContin (oxycodone): clinical pitfalls. Headache. 2004;44:44-47. Abstract
Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6:107-112. Abstract
Gourlay D, Heit HA. The art and science of urine drug testing. Clin J Pain. 2010;26:358.
Nafziger AN, Bertino JS Jr. Utility and application of urine drug testing in chronic pain management with opioids. Clin J Pain. 2009;25:73-79. Abstract
Heit HA, Gourlay DL. Urine drug testing in pain medicine. J Pain Symptom Manage. 2004;27:260-267. Abstract
Lötsch J, Geisslinger G. Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med. 2005;11:82-89.
Gourlay D, Heit HA. Commentary. Clin Chem. 2009;55:1769.
Cone EJ, Heit HA, Caplan YH, Gourlay D. Evidence of morphine metabolism to hydromorphone in pain patients chronically treated with morphine. J Anal Toxicol. 2006;30:1-5. Abstract
Reisfield GM, Chronister CW, Goldberger BA, Bertholf RL. Unexpected urine drug testing results in a hospice patient on high-dose morphine therapy. Clin Chem. 2009;55:1765-1768. Abstract
Broussard LA. Commentary. Clin Chem. 2009;55:1768.
Wasan AD, Michna E, Janfaza D, et al. Interpreting urine drug tests: prevalence of morphine metabolism to hydromorphone in chronic pain patients treated with morphine. Pain Med. 2008;9:918-923. Abstract
Cone EJ, Caplan YH, Moser F, et al. Evidence that morphine is metabolized to hydromorphone but not to oxymorphone. J Anal Toxicol. 2008;32:319-323. Abstract
McDonough PC, Levine B, Vorce S, et al. The detection of hydromorphone in urine specimens with high morphine concentrations. J Forensic Sci. 2008;53:752-754. Abstract
Chen YL, Hanson GD, Jiang X, Naidong W. Simultaneous determination of hydrocodone and hydromorphone in human plasma by liquid chromatography with tandem mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;769:55-64. Abstract
Oyler JM, Cone EJ, Joseph RE Jr., Huestis MA. Identification of hydrocodone in human urine following controlled codeine administration. J Anal Toxicol. 2000;24:530-535. Abstract
Cone EJ, Caplan YH. Urine toxicology testing in chronic pain management. Postgrad Med. 2009;121:91-102. Abstract
Sloan PA, Barkin RL. Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review. J Opioid Manag. 2008;4:131-144. Abstract
How to Dispose of Unused Medicines. US Food and Drug Administration website. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm101653.htm#guidelines. Accessed December 31, 2014.
Drug Disposal Information. Drug Enforcement Administration website. http://www.deadiversion.usdoj.gov/drug_disposal/. Accessed December 31, 2014.
Drug Enforcement Agency. Federal Register. 2014; 79(174):53520-70. Final Rule. Disposal of Controlled Substances. [Docket No. DEA-316] www.deadiversion.usdoj.gov/fed_regs/rules/2014/2014-20926.pdf. Accessed February 22, 2015.
Drug Enforcement Agency. Disposal Act: General Public Fact Sheet. http://www.deadiversion.usdoj.gov/drug_disposal/fact_sheets/disposal_public.pdf#search=Disposal Act. Accessed February 22, 2015.

It is the policy of each accrediting body that the planners, faculty, and this provider disclose the existence of any significant financial interest or other relationships that they and/or their spouse/partner may have with the manufacturers of any commercial products or services relating to the topics presented in the educational activity. Each accrediting body also requires disclosure of the intent to discuss unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose. It is the responsibility of the education committee to review potential conflicts of interest as submitted in the disclosure form and resolve such conflicts. Resolving the conflicts ensures that the content of the activities is aligned with the interests of the public. Attendees will also be informed when no relevant financial relationships exist.

Author(s)

Katherine E. Galluzzi, DO

Professor and Chair, Department of Geriatrics, Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania

Disclosures

Disclosure: Katherine E. Galluzzi, DO, has disclosed no relevant financial relationships.

Dr Galluzzi does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Galluzzi does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Barbara St. Marie, PhD, ANP, GNP, ACHPN

Associate Faculty, College of Nursing, University of Iowa, Iowa City, Iowa

Disclosures

Disclosure: Barbara St. Marie, PhD, ANP, GNP, ACHPN, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Collaborative for REMS Education

Dr St. Marie does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr St. Marie does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

Sarah Williams, PhD

Senior Scientific Director, Medscape, LLC

Disclosures

Disclosure: Sarah Williams, PhD, has disclosed no relevant financial relationships.

Independent Content Reviewers

Ronald Crossno, MD

Senior National Hospice Medical Director, Gentiva Health Services, Rockdale, Texas

Disclosures

Disclosure: Ronald Crossno, MD, has disclosed no relevant financial relationships.

Roberto Cardarelli, DO, MPH, FAAFP

University of Kentucky College of Medicine, Lexington, Kentucky

Disclosures

Disclosure: Roberto Cardarelli, DO, MPH, FAAFP, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Pfizer Inc.

Content Reviewer

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Acknowledgement
This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see here for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.

About CO*RE

CME / CE

Opioid Prescribing: Safe Practice, Changing Lives

Authors: Katherine E. Galluzzi, DO; Barbara St. Marie, PhD, ANP, GNP, ACHPN
CME / CE Released: 10/20/2015; Reviewed and Renewed: 10/19/2016
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 5/15/2017, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for neurologists, primary care physicians, other physicians, nurses (including advanced practice nurses), physician assistants, pharmacists, dentists, podiatrists, optometrists and other clinicians who may be involved in the treatment of patients who are receiving opioid therapy.

The goal of this activity is to provide education on the safe use of extended-release, long-acting opioid analgesics.

Upon completion of this activity, participants will be able to:

Describe appropriate patient assessment for treatment with ER/LA opioid analgesics
Evaluate the risks and potential benefits of ER/LA opioid analgesics
Summarize the key components of safe use of ER/LA opioid analgesics
Demonstrate accurate knowledge about how to initiate and manage therapy with ER/LA opioid analgesics, including appropriate monitoring for adverse effects and possible misuse

Disclosures

Author(s)

Katherine E. Galluzzi, DO

Professor and Chair, Department of Geriatrics, Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania

Disclosures

Disclosure: Katherine E. Galluzzi, DO, has disclosed no relevant financial relationships.

Dr Galluzzi does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Galluzzi does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Barbara St. Marie, PhD, ANP, GNP, ACHPN

Associate Faculty, College of Nursing, University of Iowa, Iowa City, Iowa

Disclosures

Disclosure: Barbara St. Marie, PhD, ANP, GNP, ACHPN, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Collaborative for REMS Education

Dr St. Marie does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr St. Marie does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

Sarah Williams, PhD

Senior Scientific Director, Medscape, LLC

Disclosures

Disclosure: Sarah Williams, PhD, has disclosed no relevant financial relationships.

Independent Content Reviewers

Ronald Crossno, MD

Senior National Hospice Medical Director, Gentiva Health Services, Rockdale, Texas

Disclosures

Disclosure: Ronald Crossno, MD, has disclosed no relevant financial relationships.

Roberto Cardarelli, DO, MPH, FAAFP

University of Kentucky College of Medicine, Lexington, Kentucky

Disclosures

Disclosure: Roberto Cardarelli, DO, MPH, FAAFP, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Pfizer Inc.

Content Reviewer

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

About CO*RE

Accreditation Statements

For Physicians

Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

This Enduring Material activity, Opioid Prescribing: Safe Practice, Changing Lives has been reviewed and is acceptable for up to 2.00 Prescribed credit(s) by the American Academy of Family Physicians. Term of approval begins 03/24/2015. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Physician Assistants

This program has been reviewed and is approved for a maximum of 2 hours of AAPA Category I CME credit by the Physician Assistant Review Panel. Approval is valid for one year from the issue date. Participants may submit the self-assessment at any time during that period.

This program was planned in accordance with AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

Successful completion of the self-assessment is required to earn Category I CME credit. Successful completion is defined as a cumulative score of at least 70% correct.

Contact This Provider

For Nurses

Medscape, LLC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded 2.0 contact hour(s) of continuing nursing education for RNs and APNs; 2.0 contact hours are in the area of pharmacology.

For Nurse Practitioners

This program is approved for 2.0 contact hours of continuing education (which includes 2.0 hours of pharmacology) by the American Association of Nurse Practitioners. Program ID 1307268

This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.

Contact This Provider

For Pharmacists

Medscape, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Medscape designates this continuing education activity for 2.0 contact hour(s) (0.20 CEUs) (Universal Activity Number 0461-0000-15-122-H05-P)

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Neurology & Neurosurgery

CME / CE

Opioid Prescribing: Safe Practice, Changing Lives

Authors: Katherine E. Galluzzi, DO; Barbara St. Marie, PhD, ANP, GNP, ACHPNFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / CE Released: 10/20/2015; Reviewed and Renewed: 10/19/2016

Valid for credit through: 5/15/2017, 11:59 PM EST

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Section 1. Assessing Patients and Initiating Opioid Therapy

How do you decide whether an ER/LA opioid is appropriate?
Katherine E. Galluzzi, DO; Barbara St Marie, PhD, ANP-BC, GNP-BC, ACHPN

Section 2. Managing and Monitoring Therapy

Recognizing the red flags to possible misuse.
Katherine E. Galluzzi, DO

Section 3. A Summary of Take-Home Messages

A quick review of the practice pearls.
Katherine E. Galluzzi, DO

Page 1 of 17

Introduction

CME / CE Information

Additional Resources

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Author(s)

Katherine E. Galluzzi, DO

Barbara St. Marie, PhD, ANP, GNP, ACHPN

Editor(s)

Sarah Williams, PhD

Independent Content Reviewers

Ronald Crossno, MD

Roberto Cardarelli, DO, MPH, FAAFP

Content Reviewer

Nafeez Zawahir, MD

CME / CE

Opioid Prescribing: Safe Practice, Changing Lives

Target Audience and Goal Statement

Disclosures

Author(s)

Katherine E. Galluzzi, DO

Barbara St. Marie, PhD, ANP, GNP, ACHPN

Editor(s)

Sarah Williams, PhD

Independent Content Reviewers

Ronald Crossno, MD

Roberto Cardarelli, DO, MPH, FAAFP

Content Reviewer

Nafeez Zawahir, MD

Accreditation Statements

For Physicians

For Physician Assistants

For Nurses

For Nurse Practitioners

For Pharmacists

Instructions for Participation and Credit

Opioid Prescribing: Safe Practice, Changing Lives

Contents of This CME Activity